Commodore Capital LP bought a new stake in Athira Pharma, Inc. (NASDAQ:ATHA – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 464,398 shares of the company’s stock, valued at approximately $3,515,000. Commodore Capital LP owned approximately 11.77% of Athira Pharma as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently bought and sold shares of ATHA. Spruce Street Capital LP acquired a new position in Athira Pharma during the fourth quarter valued at approximately $2,980,000. ADAR1 Capital Management LLC acquired a new position in shares of Athira Pharma during the 4th quarter worth approximately $2,891,000. Renaissance Technologies LLC raised its stake in shares of Athira Pharma by 44.7% during the 4th quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after purchasing an additional 23,223 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Athira Pharma during the 4th quarter worth about $100,000. Finally, Focus Partners Wealth bought a new stake in shares of Athira Pharma in the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 57.12% of the company’s stock.
Athira Pharma Price Performance
ATHA stock opened at $8.22 on Thursday. The company has a fifty day moving average price of $9.39 and a two-hundred day moving average price of $7.42. Athira Pharma, Inc. has a one year low of $0.23 and a one year high of $8.36. The stock has a market cap of $32.42 million, a price-to-earnings ratio of -0.85 and a beta of 2.79.
Athira Pharma Profile
Athira Pharma, Inc is a clinical?stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease?modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira’s pipeline is fosgonimeton (ATH?1017), a small?molecule positive modulator of the HGF/MET system.
See Also
- Five stocks we like better than Athira Pharma
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
